4 completed, 2 withdrawn. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Withdrawn 2 |
Follow DOXO-EMCH: new trials by email Literature Review of DOXO-EMCH trials Research Report on DOXO-EMCH
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Nab-paclitaxel, Cisplatin, 5Fluorouracil - Non Small Cell Lung Cancer | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-06-01 | 2025-02-21 | |
| Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Aldoxorubicin, Topotecan - Metastatic Small Cell Lung Cancer | Phase 2 | Completed | ImmunityBio, Inc. | 135 | 2015-04-20 | 2024-06-25 |
| Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma 250 mg/m2 aldoxorubicin, 350 mg/m2 aldoxorubicin - Glioblastoma | Phase 2 | Completed | ImmunityBio, Inc. | 28 | 2014-03-01 | 2024-05-29 |
| Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer INNO-206 - Pancreatic Ductal Adenocarcinoma | Phase 2 | Completed | ImmunityBio, Inc. | 15 | 2012-05-16 | 2024-06-06 |
| Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma INNO-206, Doxorubicin - Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma | Phase 2 | Completed | ImmunityBio, Inc. | 126 | 2012-01-11 | 2024-05-29 |
| INNO-206 in Patients With Small Cell Lung Cancer (SCLC) INNO-206 - Small Cell Lung Cancer | Phase 2 | Withdrawn | CytRx | 2008-05-01 | 2012-02-09 |
Small Cell Lung Carcinoma (2) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Glioblastoma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Sarcoma (1)
ImmunityBio, Inc. (5) · CytRx (1)
United States (6) · Hungary (2) · Australia (1) · India (1) · Romania (1) · Russia (1) · Spain (1) · Ukraine (1)
Daniel Levitt, M.D., Ph.D. (1) · Daniel Levitt, MD, PhD (1) · Daniel Von Hoff, MD, FACP (1) · Michael Maitland, MD (1) · Sant Chawla, M.D. (1)